Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

Carpal Tunnel Syndrome Clinical Trial

Official title:

Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02792790
• Other study ID #: 16-158
• Status: Completed
• Start date: March 2016
• Est. completion date: December 2, 2021

Study information

• Verified date: December 2021
• Source: The Cleveland Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators will prospectively evaluate tissue samples obtained from patients undergoing carpal tunnel release surgery for amyloid in the soft tissue that is removed. Patients who have tissue that stains positive for amyloid will undergo cardiac testing to look for evidence of cardiac involvement.

Description:

Since the 1970s, the connection between amyloidosis and carpal tunnel syndrome has been described, with tenosynovial tissue staining positive for amyloid fibril deposition. Up to 30% of patients in prior studies with idiopathic carpal tunnel syndrome have biopsy tissue that stains positive for amyloid deposition. However, the prevalence of cardiac involvement at the time of carpal tunnel syndrome surgery has not been established. Furthermore, the role of TTR kinetic stability in the disease progression of amyloidosis is unclear. Diagnosing TTR amyloidosis at the time of carpal tunnel involvement could lead to an earlier identification of the disease at a stage where the cardiomyopathy may be occult or less advanced. In addition, abnormal TTR kinetics may even precede tissue deposition in the flexor tendon retinaculum. As several emerging pharmacological strategies are in development that may slow or even halt TTR amyloidosis, earlier diagnosis is advantageous. Identification and implementation of therapy for prevention or early disease treatment may alter the natural history of this progressive systemic disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: December 2, 2021
• Est. primary completion date: July 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Males = 50 years of age
• Females = 60 years of age
• Undergoing carpal tunnel release surgery (adequate symptoms are not responding to conservative management requiring surgery)
• Able to consent
• Underwent carpal tunnel surgery and biopsy within last 30 days, if the study was discussed prior to surgery by one of the study physicians.

Exclusion Criteria:

• Secondary CTS (Hemodialysis, rheumatoid arthritis, trauma)
• Known diagnosis of amyloidosis

Related Conditions & MeSH terms

• Amyloidosis
• Cardiomyopathies
• Cardiomyopathy
• Carpal Tunnel Syndrome
• Senile Systemic Amyloidosis
• Syndrome
• Transthyretin Amyloidosis

Locations

Country	Name	City	State
United States	Lutheran Hospital	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of transthyretin (TTR) amyloidosis in patients undergoing carpal tunnel release surgery	Identify the incidence of TTR amyloid deposits in the soft tissue of patients undergoing carpal tunnel surgery for idiopathic carpal tunnel syndrome	Biopsy completed on day of surgery
Primary	Cardiac progression of transthyretin (TTR) amyloidosis in carpal tunnel biopsy-positive patients	Assess the progression of cardiac disease in patients with TTR deposits found in soft tissue removed at the time of carpal tunnel surgery	4 years from baseline cardiac assessment.
Secondary	Prevalence of abnormal transthyretin (TTR) kinetics in patients undergoing carpal tunnel surgery	Identify the prevalence of abnormal TTR kinetics in patients undergoing carpal tunnel surgery for idiopathic carpal tunnel syndrome (develop a new test that aids identification of misfolded TTR intermediates that is more specific and sensitive to diagnosis this disease in the blood or tissue)	One-time kinetics test for biopsy-negative patients; baseline kinetics and annually for 4 years in biopsy-positive patients
Secondary	Early transthyretin (TTR) amyloid cardiomyopathy identification in carpal tunnel biopsy-positive patients	Investigate whether early TTR cardiomyopathy can be identified in patients who have TTR amyloid deposits identified in the soft tissue removed at the time of carpal tunnel surgery using cardiac biomarkers, echocardiography with strain, and nuclear bone scintigraphy	Baseline and annual testing for 4 years in biopsy-positive patients